After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Travere Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Travere Therapeutics Inc is $441.38M. A total of 0.97 million shares were traded on the day, compared to an average of 1.18M shares.
In the most recent transaction, Cline Christopher R. sold 54 shares of TVTX for 6.74 per share on Apr 11 ’24. After the transaction, the CHIEF FINANCIAL OFFICER now owns 70,849 company shares. In a previous transaction on Feb 01 ’24, Dube Eric M sold 19,122 shares at 8.70 per share. TVTX shares that CHIEF EXECUTIVE OFFICER owns now total 350,600.
Among the insiders who sold shares, REED ELIZABETH E disposed of 4,764 shares on Feb 01 ’24 at a per-share price of $8.71. This resulted in the SVP, GC & CORPORATE SECRETARY holding 76,270 shares of TVTX after the transaction. In another insider transaction, ROTE WILLIAM E. sold 4,764 shares at $8.71 per share on Feb 01 ’24. Company shares held by the SENIOR VICE PRESIDENT, R&D now total 80,720.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, TVTX has a high of $22.75 and a low of $5.25.
As of this writing, TVTX has an earnings estimate of $Avalo Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of TG Therapeutics, Inc. estimates, with a high estimate of $Travere Therapeutics, Inc. per share and a lower estimate of $Theratechnologies Inc..
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. TVTX’s latest balance sheet shows that the firm has $552.88M in Cash & Short Term Investments as of fiscal 2021. There were $261.99M in debt and $124.09M in liabilities at the time. Its Book Value Per Share was $2.66, while its Total Shareholder’s Equity was $302.11M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TVTX is Buy with a score of 4.50.
